Companies › Chengdu Suncadia Medicine
3 active drug programs in 5 registered trials: 2 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Genitourinary, Hematology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HRS-5965 FD inhibitor (Factor D inhibitor) | – | Phase 3 | Primary IgA Nephropathy; Paroxysmal Nocturnal Hemoglobinuria | Oct 2027 |
| HRS-5765 | – | Phase 1 | Heart Failure | Dec 2026 |
| HRS-1635 | – | Phase 1 | B-cell Malignancy | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07551167 | HRS-5765 | Phase 1 | Heart Failure | Cardiovascular | Dec 2026 |
| NCT07014826 | HRS-5965 | Phase 3 | Primary IgA Nephropathy | Genitourinary | Oct 2027 |
| NCT06238544 | HRS-5965 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Dec 2027 |
| NCT07583212 | HRS-1635 | Phase 1 | B-cell Malignancy | Oncology | Oct 2028 |
| NCT07582133 | HRS-5965 | Phase 2 | Primary IgA Nephropathy | Genitourinary | Jul 2029 |
No annotated target.
–
Kind Pharmaceuticals Biocity Biopharmaceutics Iperboreal Pharma Srl Apellis Pharmaceuticals Shenzhen Kangzhe Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.